Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Oxford Nanopore Technologies and Day Zero Diagnostics Collaborate on Sepsis Diagnostic Development

NextEdge Admin

11 Nov 2023

2 min 21 sec

Oxford Nanopore Technologies and Day Zero Diagnostics have joined forces to create a comprehensive diagnostic solution for bloodstream infections, as announced on Tuesday. While the financial details of the collaboration remain undisclosed, the two companies intend to develop an end-to-end system that facilitates same-day identification and genomics-based antibiotic susceptibility profiling without relying on blood culture.

The planned diagnostic system will integrate Day Zero Diagnostics’ ultra-high enrichment sample preparation technology and AI-driven Keynome microbial identification and antibiotic susceptibility pipeline with sequencing reads from Oxford Nanopore’s high-throughput PromethIon 2 Solo. This collaboration aims to achieve culture-free, same-day organism identification directly from native samples, marking a significant advancement in infectious disease diagnostics. Jong Lee, CEO and co- founder of Day Zero Diagnostics, expressed optimism about the collaboration, highlighting its potential to enable early and targeted treatment for patients.

Both companies are committed to seeking regulatory approvals for the system, including from the US Food and Drug Administration. The goal is to provide a rapid, accurate, and accessible solution for combating bloodstream infections. Gordon Sanghera, CEO of Oxford Nanopore Technologies, expressed hope that the combined strengths of their technology and Day Zero Diagnostics’ expertise would enhance accessibility to an effective solution in the fight against infections.

Beyond the diagnostic platform development partnership, Day Zero Diagnostics has also signed an agreement to leverage Oxford Nanopore’s platforms for sequencing and analysis as part of its epiXact lab services catering to commercial customers.